Friday, June 13, 2014
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.
Tuesday, April 15, 2014
Healthcare represents less than one per cent of the ASX, one of the world’s most dynamic growth sectors.
That’s why most Aussie healthcare stocks trade at what’s known as a ‘scarcity premium’.
Encompassing healthcare facilities, drug and biotechnology stocks, and medical equipment suppliers and manufacturers, the overall quality and performance of Australian healthcare stocks is impressive. Half of the top 10 achieved Skaffold’s preferred stock ratings of A1, A2, B1 and B2 based on their latest financial reports.
Despite a recent sell off, which has seen share prices of the top 10 fall, on average, 3% since late February, safety margins continue to be high, ranging between -15 and -75 per cent.
With the ‘scarcity premium’ enshrouding local healthcare stocks, we went in search of better healthcare value stocks offshore and found 6 standouts.